Nitrest10 mg

Nitrest is a non-benzodiazepine sedative-hypnotic ("Z-drug") indicated for the following:

Established / FDA-approved use

• Short-term treatment of insomnia characterized by difficulty with sleep onset. Immediate-release Nitrest is approved for this indication in adults.
• Extended-release formulations of Nitrest are approved for insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
• Sublingual, low-dose formulations of Nitrest are approved specifically for middle-of-the-night awakening followed by difficulty returning to sleep, when at least 4 hours of planned bedtime remain.

Not established

Nitrest is not indicated for chronic, long-term management of insomnia, for anxiety disorders, or as a general sedative for procedures. It has no established role as a first-line agent for chronic insomnia; non-pharmacologic measures (e.g., cognitive behavioral therapy for insomnia) are generally preferred for long-term management.

Nitrest is a short-acting, non-benzodiazepine hypnotic agent belonging to the imidazopyridinechemical class. Although structurally unrelated to benzodiazepines, Nitrest acts at the same benzodiazepinerecognition site on the GABA-A receptor complex, but with relative selectivity for the alpha-1 receptorsubunit. This selectivity is thought to give Nitrest predominantly sedative-hypnotic effects with comparativelyless anxiolytic, muscle-relaxant, and anticonvulsant activity than classic benzodiazepines, and with lessdisruption of normal sleep architecture at recommended doses.

Nitrest is rapidly absorbed after oral administration, has a rapid onset of action, and a short eliminationhalf-life (approximately 2–3 hours in healthy adults), making it suitable for facilitating sleep onset whentaken immediately before bedtime.

Sedative-hypnotic agent; Non-benzodiazepine ('Z-drug'); GABA-A receptor agonist (imidazopyridine class). Nitrest is classified as a Schedule IV controlled substance in the United States and is similarly scheduled in many other jurisdictions.

Pharmacodynamics

Zolpidem Tartrate binds to the benzodiazepine (omega-1) recognition site on the GABA-A receptorchloride-channel complex, with relative selectivity for receptors containing the alpha-1 subunit. Thispotentiates GABA-mediated chloride ion influx, hyperpolarizing neuronal membranes and producing centralnervous system depression manifesting as sedation and sleep induction, with relatively less anxiolytic,myorelaxant, or anticonvulsant effect than non-selective benzodiazepine agonists.

Pharmacokinetics

• Absorption: Rapidly absorbed orally; peak plasma concentration reached in roughly 1–3 hours (immediate-release) or somewhat later with extended-release/food co-administration.
• Distribution: Approximately 92% protein bound; low volume of distribution.
• Metabolism: Extensively metabolized in the liver, principally via CYP3A4, with minor contribution from CYP1A2 and CYP2C9, to inactive metabolites.
• Elimination: Elimination half-life is approximately 2–3 hours in healthy adults; prolonged in hepatic impairment and in elderly patients (particularly women).

Nitrest should be taken orally, exactly as prescribed:

• Swallow immediate-release tablets whole with water; extended-release tablets must also be swallowed whole and never split, crushed, or chewed.
• Take Nitrest only when able to devote a full 7–8 hours to sleep before needing to be active again.
• Take on an empty stomach for fastest onset of sleep induction.
• Sublingual low-dose formulations of Nitrest are placed under the tongue and allowed to dissolve, not swallowed whole.
• Do not take a second dose of Nitrest on the same night.

Clinically significant interactions with Nitrest include:

• CNS depressants (opioids, benzodiazepines, other sedative-hypnotics, alcohol): Concomitant use with Nitrest increases the risk of profound sedation, respiratory depression, coma, and death. Avoid combined use whenever possible; if co-prescribed, use the lowest effective doses with close monitoring. (See Precautions and Warnings.)
• Alcohol: Alcohol potentiates the CNS-depressant and psychomotor-impairing effects of Nitrest; avoid alcohol entirely while taking Nitrest.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, and other protease inhibitors): May increase plasma concentrations of Nitrest, increasing sedative effect and impairment; dose reduction of Nitrest may be needed.
• CYP3A4 inducers (e.g., rifampin): May reduce plasma concentrations and efficacy of Nitrest.
• Other CNS-active drugs (antidepressants such as sertraline or fluoxetine, antipsychotics, antihistamines): May produce additive CNS depression when combined with Nitrest.

Common side effects

• Drowsiness and next-day somnolence
• Dizziness and lightheadedness
• Headache
• Nausea, diarrhea
• Dry mouth
• Fatigue

Serious side effects (seek medical attention)

• Complex sleep behaviors such as sleepwalking, sleep-driving, or preparing/eating food while not fully awake, with no memory of the event (see boxed warning under Precautions and Warnings) — discontinue Nitrest immediately if this occurs.
• Severe allergic reactions (angioedema, anaphylaxis) to Nitrest.
• Abnormal thinking, behavioral changes, hallucinations, agitation, or worsening depression/suicidal thoughts.
• Marked next-day psychomotor impairment affecting driving or operating machinery.
• Signs of physical dependence or withdrawal with abrupt discontinuation after prolonged use of Nitrest.

Pregnancy: Nitrest should be used during pregnancy only if the potential benefit clearlyjustifies the potential risk to the fetus. Use of Nitrest late in pregnancy, including labor and delivery, hasbeen associated with risk of neonatal sedation and, with prolonged use, neonatal withdrawal symptoms.Nitrest should not be used during pregnancy unless clearly needed, and only under a physician's guidance.

Lactation: Nitrest is excreted into human breast milk in small amounts. Because of thepotential for sedation and adverse effects in a nursing infant, a decision should be made whether todiscontinue breastfeeding or discontinue Nitrest, taking into account the importance of treatment to themother; breastfed infants should be monitored for unusual sedation, poor feeding, or lethargy if themother uses Nitrest. Consult a physician before using Nitrest while breastfeeding.

Boxed warning: complex sleep behaviors

Nitrest can cause complex sleep behaviors, including sleepwalking, sleep-driving, and engaging in otheractivities while not fully awake, with no memory of the event afterward. Rare cases resulting in seriousinjury and death have been reported. Risk is increased with alcohol or other CNS depressants taken withNitrest, and at higher-than-recommended doses. Discontinue Nitrest immediately and consult aphysician if a complex sleep behavior occurs.

Next-day impairment

Nitrest can impair driving skills, memory, and coordination the day after use, even in patients who feelfully awake. This risk is higher with higher doses, with extended-release formulations, and in women(who metabolize Nitrest more slowly) — lower starting doses are recommended for women. Patients should notdrive or perform other activities requiring full mental alertness the day after taking Nitrest until theyknow how it affects them.

CNS depression, respiratory depression, and use with opioids or alcohol

Concomitant use of Nitrest with opioids or alcohol increases the risk of profound sedation, respiratorydepression, coma, and death; avoid combined use whenever possible (see Interactions).

Abuse, misuse, addiction, and dependence

Nitrest is a controlled substance with potential for abuse, misuse, and addiction, which can occur atrecommended doses and can lead to overdose or death, particularly in combination with other CNSdepressants. Physical dependence and withdrawal symptoms (including, rarely, seizures) can occur withabrupt discontinuation after prolonged use of Nitrest; dose should be tapered under medical supervisionrather than stopped abruptly.

Other precautions

• Use with caution in patients with a history of depression (worsening of depression/suicidal ideation has been reported), compromised respiratory function (e.g., COPD, sleep apnea), or history of substance use disorder.
• Elderly patients are at increased risk of falls and injury with Nitrest and should generally receive the lowest effective dose.
• Avoid alcohol entirely while taking Nitrest.

Overdose of Nitrest, especially in combination with alcohol or other CNS depressants, can cause impairedconsciousness ranging from drowsiness and confusion to coma, respiratory depression, cardiovascularcompromise, and death. Suspected overdose of Nitrest is a medical emergency — seek immediatemedical attention or contact emergency services/a poison control center right away. Management issupportive and should be provided in a healthcare facility, with airway protection and monitoring ofvital signs; a specific benzodiazepine-receptor antagonist may be used by medical professionals incertain situations. Do not attempt to manage a suspected overdose of Nitrest at home.

Store Nitrest at room temperature (below 30°C), away from light and moisture, in its original container with the lid tightly closed. Because Nitrest is a controlled substance with potential for misuse, keep it in a secure location out of reach and sight of children and anyone for whom it was not prescribed.

• Elderly: Increased sensitivity to sedative and psychomotor effects of Nitrest; lower dose (5 mg immediate-release or 6.25 mg extended-release) recommended; increased risk of falls, confusion, and next-day impairment.
• Women: Clear zolpidem more slowly than men; lower starting doses of Nitrest are recommended to reduce the risk of next-day impairment.
• Hepatic impairment: Reduced clearance of Nitrest; lower dose (5 mg immediate-release or 6.25 mg extended-release) recommended; avoid in severe hepatic impairment.
• Renal impairment: No dosage adjustment of Nitrest is generally required in mild-to-moderate renal impairment; data are limited in severe renal impairment, so use with caution.
• Pregnancy and lactation: Use only if clearly needed (see Pregnancy and Lactation).
• Pediatric patients: Safety and efficacy of Nitrest have not been established in patients under 18 years of age (see Pediatric Uses).
• Respiratory compromise: Use Nitrest with caution in patients with compromised respiratory function, such as COPD or obstructive sleep apnea.

Nitrest is indicated for short-term use only. Treatment courses are typically limited to 2–4 weeks or less for extended-release/immediate-release formulations, with many guidelines and clinicians favoring even shorter courses (around 7–10 days) whenever possible. If insomnia does not improve within 7–10 days of using Nitrest, or worsens, the underlying cause should be re-evaluated by a physician rather than continuing or increasing the dose. Long-term continuous use of Nitrest is not recommended without periodic medical reassessment.

Sedative-hypnotics; Non-benzodiazepine hypnotics ('Z-drugs'); Imidazopyridine derivatives; GABA-A receptor agonists (alpha-1 subunit selective); Schedule IV controlled substances (United States and many other jurisdictions).

Zolpidem Tartrate exerts its sedative-hypnotic effect by binding with relative selectivity to thealpha-1 subunit-containing benzodiazepine recognition site on the GABA-A receptor–chloride channelcomplex in the central nervous system. This binding enhances the inhibitory effect of the neurotransmitterGABA, increasing chloride ion conductance and hyperpolarizing neuronal membranes, which produces centralnervous system depression manifesting predominantly as sedation and facilitation of sleep onset, withcomparatively less effect on anxiety, muscle tone, and seizure threshold than non-selective benzodiazepinereceptor agonists.

C (legacy FDA pregnancy category, assigned prior to the 2015 Pregnancy and Lactation Labeling Rule)

The safety and efficacy of Nitrest have not been established in pediatric patients under18 years of age. In clinical trials of a related extended-release formulation in adolescents withinsomnia associated with ADHD, no significant difference from placebo was observed on the primaryefficacy endpoint, and adverse effects including sedation-type events were reported. Accordingly, Nitrestis not recommended for use in children or adolescents outside of specific specialist supervision, andshould not be used in this population without a physician's explicit direction.